173 related articles for article (PubMed ID: 32783569)
1. Next generation flow cytometry for MRD detection in patients with AL amyloidosis.
Kastritis E; Kostopoulos IV; Theodorakakou F; Fotiou D; Gavriatopoulou M; Migkou M; Tselegkidi MI; Roussou M; Papathoma A; Eleutherakis-Papaioakovou E; Dialoupi I; Kanellias N; Ntalianis A; Rousakis P; Trougakos IP; Tsitsilonis O; Gakiopoulou C; Terpos E; Dimopoulos MA
Amyloid; 2021 Mar; 28(1):19-23. PubMed ID: 32783569
[TBL] [Abstract][Full Text] [Related]
2. The Quantification of Minimal Residual Disease Pre- and Post-Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia.
Wang XY; Fan QZ; Xu LP; Wang Y; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Liu YR; Mo XD; Liu KY; Huang XJ; Chang YJ
Cytometry B Clin Cytom; 2020 Jan; 98(1):75-87. PubMed ID: 31424628
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.
Palladini G; Paiva B; Wechalekar A; Massa M; Milani P; Lasa M; Ravichandran S; Krsnik I; Basset M; Burgos L; Nuvolone M; Lecumberri R; Foli A; Puig N; Sesta MA; Bozzola M; Cascino P; Nevone A; Ripepi J; Berti P; Casarini S; Annibali O; Orfao A; San-Miguel J; Merlini G
Blood Cancer J; 2021 Feb; 11(2):34. PubMed ID: 33594045
[TBL] [Abstract][Full Text] [Related]
4. Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.
Sidana S; Muchtar E; Sidiqi MH; Jevremovic D; Dispenzieri A; Gonsalves W; Buadi F; Lacy MQ; Hayman SR; Kourelis T; Kapoor P; Go RS; Warsame R; Leung N; Rajkumar SV; Kyle RA; Gertz MA; Kumar SK
Am J Hematol; 2020 May; 95(5):497-502. PubMed ID: 32010993
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
[No Abstract] [Full Text] [Related]
6. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
Walter RB; Buckley SA; Pagel JM; Wood BL; Storer BE; Sandmaier BM; Fang M; Gyurkocza B; Delaney C; Radich JP; Estey EH; Appelbaum FR
Blood; 2013 Sep; 122(10):1813-21. PubMed ID: 23847197
[TBL] [Abstract][Full Text] [Related]
7. Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.
Staron A; Burks EJ; Lee JC; Sarosiek S; Sloan JM; Sanchorawala V
Blood Adv; 2020 Mar; 4(5):880-884. PubMed ID: 32130406
[TBL] [Abstract][Full Text] [Related]
8. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
[TBL] [Abstract][Full Text] [Related]
9. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
Pasvolsky O; Pasyar S; Bassett RL; Khan HN; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Cancer; 2024 May; 130(9):1663-1672. PubMed ID: 38127583
[TBL] [Abstract][Full Text] [Related]
10. The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts.
Liu J; Ma R; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Fan QZ; Huang XJ; Chang YJ
Bone Marrow Transplant; 2019 Apr; 54(4):567-577. PubMed ID: 30127465
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.
Tschautscher MA; Jevremovic D; Rajkumar V; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Hwa YL; Fonder AL; Hobbs MA; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Lin Y; Gonsalves WI; Kourelis T; Warsame R; Kyle RA; Kumar SK
Am J Hematol; 2019 Jul; 94(7):751-756. PubMed ID: 30945330
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.
Sato K; Okazuka K; Ishida T; Sakamoto J; Kaneko S; Nashimoto J; Uto Y; Ogura M; Yoshiki Y; Abe Y; Maeda A; Hamazaki H; Tsukada N; Hiragohri Y; Suzuki K
Ann Hematol; 2021 Dec; 100(12):2989-2995. PubMed ID: 34430990
[TBL] [Abstract][Full Text] [Related]
13. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.
Chang YJ; Wang Y; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ
J Hematol Oncol; 2017 Jul; 10(1):134. PubMed ID: 28676064
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.
Li X; Huang B; Liu J; Chen M; Gu J; Li J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):913-919. PubMed ID: 33966111
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.
Bansal R; Baksh M; Larsen JT; Hathcock MA; Dingli D; Stewart AK; Kapoor P; Kourelis T; Hayman SR; Warsame RM; Fonseca R; Bergsagel PL; Ailawadhi S; Kumar SK; Lin Y
Blood Cancer J; 2023 Apr; 13(1):47. PubMed ID: 37019896
[TBL] [Abstract][Full Text] [Related]
16. Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis.
Dispenzieri A; Arendt B; Dasari S; Kohlhagen M; Kourelis T; Kumar SK; Leung N; Muchtar E; Buadi FK; Warsame R; Kyle RA; Lacy MQ; Dingli D; Kapoor P; Gonsalves WI; Go RS; Hayman SR; Hwa YL; Fonder A; Hobbs M; Jevremovic D; Lust JA; Zeldenrust S; Russell SJ; Rajkumar SV; Gertz MA; Murray D
Blood Cancer J; 2020 Feb; 10(2):20. PubMed ID: 32098948
[TBL] [Abstract][Full Text] [Related]
17. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
Paiva B; Puig N; Cedena MT; Rosiñol L; Cordón L; Vidriales MB; Burgos L; Flores-Montero J; Sanoja-Flores L; Lopez-Anglada L; Maldonado R; de la Cruz J; Gutierrez NC; Calasanz MJ; Martin-Ramos ML; Garcia-Sanz R; Martinez-Lopez J; Oriol A; Blanchard MJ; Rios R; Martin J; Martinez-Martinez R; Sureda A; Hernandez MT; de la Rubia J; Krsnik I; Moraleda JM; Palomera L; Bargay J; Van Dongen JJM; Orfao A; Mateos MV; Blade J; San-Miguel JF; Lahuerta JJ;
J Clin Oncol; 2020 Mar; 38(8):784-792. PubMed ID: 31770060
[TBL] [Abstract][Full Text] [Related]
18. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.
Takamatsu H; Yoroidaka T; Fujisawa M; Kobori K; Hanawa M; Yamashita T; Murata R; Ueda M; Nakao S; Matsue K
Int J Hematol; 2019 Apr; 109(4):377-381. PubMed ID: 30778767
[TBL] [Abstract][Full Text] [Related]
19. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?
Lee H; Duggan P; Neri P; Tay J; Bahlis NJ; Jimenez-Zepeda VH
Bone Marrow Transplant; 2017 Jun; 52(6):915-917. PubMed ID: 28287637
[No Abstract] [Full Text] [Related]
[Next] [New Search]
